 MINNEAPOLIS, Feb. 08, 2021 GLOBE NEWSWIRE -- Predictive Oncology NASDAQ: POAI, a knowledge-driven company focused on applying artificial intelligence AI to personalized medicine and drug discovery, announced today that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform PeDALTM. The project will use PeDAL to rapidly and cost-effectively profile panel of existing drugs against hundreds of patient cell lines. This process will generate data on which compounds are active against which specific patient profiles, delivering both proof data for the PeDAL approach and valuable Intellectual Property IP for the company. 